See how research connects peptides to biological targets, signaling pathways, and biological processes.
This tool shows, for each peptide, which biological target the available research points to, how directly that relationship is supported, and how it connects to broader signaling pathways and biological processes. It describes what research suggests about biological mechanisms -- not proven health or treatment outcomes, and not medical advice. See each peptide's full research profile for complete detail, citations, and safety information.
The complete mechanism research history, including peptides outside the current catalog. Nothing here has been removed or invalidated -- it remains fully documented for reference.
Showing 83 of 83 peptides
Evidence legend
Relationship support
Directly supported
Supported indirectly
Inferred from related evidence
Uncertain
Evidence context
Human research
Preclinical research
Human + preclinical research
Review / established literature
Related compound/program context
Evidence context uncertain
Understanding mechanism evidence
This tool describes research into biological targets, signaling pathways, and biological processes -- not proven health or treatment outcomes, and not medical advice. Relationship-support and evidence-context labels describe the type and directness of research available, not proof of safety or effectiveness. See each peptide's full research profile for complete detail, citations, and safety information.
Mechanism profiles
Arginine Vasopressin (AVP)
2 mechanism branches · Directly supported · Human research
Signal / mechanism stepV1A receptor activationAVP directly activates AVPR1A on vascular smooth muscle, demonstrated by hemodynamic/pressor effect in randomized human trials and the Vasostrict FDA-approved indication.
Signal / mechanism stepGq/11 -> PLC -> IP3/DAG -> intracellular Ca2+Textbook downstream Gq/11-coupled cascade for V1A engagement; not itself the focus of the cited hemodynamic-outcome trials.
Systemic vascular resistance / blood pressure increase (V1A-mediated vasoconstriction) — contributes to the pathway (structural link, no support rating)Sources: avp-dunser-2003-pmid12732600
A specific pathway family has not yet been assigned for this relationship.
A biological process is not the same as a proven health or treatment outcome.
VASST's primary 28-day mortality endpoint was not statistically significant -- hemodynamic/pressor effect is well supported, mortality benefit is not. No dedicated in vitro V1A receptor-binding assay is cited; evidence is human outcome/hemodynamic trials plus the Vasostrict FDA label's approved indication.
Sources
Central Citation Library reference: avp-vasst-2008-pmid18305265
Central Citation Library reference: avp-dunser-2003-pmid12732600
Central Citation Library reference: avp-vasostrict-dailymed-label
What is established
A target relationship (V1A receptor (vascular)) is documented.
What remains unclear
A specific pathway family has not yet been assigned.
VASST's primary 28-day mortality endpoint was not statistically significant -- hemodynamic/pressor effect is well supported, mortality benefit is not. No dedicated in vitro V1A receptor-binding assay is cited; evidence is human outcome/hemodynamic trials plus the Vasostrict FDA label's approved indication.
Looking for research areas instead?
Peptide Explorer shows what areas a peptide is researched in. This tool shows how the underlying biology appears to work.
Educational use only. Not medical advice. MitoCore Biosciences does not diagnose, treat, cure, prevent, prescribe, sell peptides, recommend dosing, or provide instructions for human use.
